Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Andre VerhoekParneet CheemaBarbara MeloskyBenoit SamsonFrances A ShepherdFilippo de MarinisThomas JohnYi-Long WuBart HeegNadia Van DalfsenBenjamin BrackeMiguel MirandaSimon ShawDaniel MoldaverPublished in: PharmacoEconomics - open (2023)
In this cost-effectiveness assessment, adjuvant osimertinib was cost-effective compared with active surveillance for patients with completely resected stage IB‒IIIA EGFRm NSCLC after SoC.